D R Bolin
Overview
Explore the profile of D R Bolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tannu S, Renzetti L, Tare N, Ventre J, Lavelle D, Lin T, et al.
Br J Pharmacol
. 2010 Aug;
161(6):1329-42.
PMID: 20735404
Background And Purpose: Vasoactive intestinal peptide is expressed in the respiratory tract and induces its effects via its receptors, VPAC(1) and VPAC(2). RO5024118 is a selective VPAC(2) receptor agonist derived...
2.
Bolin D, Swain A, Sarabu R, Berthel S, Gillespie P, Huby N, et al.
J Med Chem
. 2000 Jun;
43(11):2135-48.
PMID: 10841792
Molecular features of ligand binding to MHC class II HLA-DR molecules have been elucidated through a combination of peptide structure-activity studies and structure-based drug design, resulting in analogues with nanomolar...
3.
Falcioni F, Ito K, Vidovic D, Belunis C, Campbell R, Berthel S, et al.
Nat Biotechnol
. 1999 Jun;
17(6):562-7.
PMID: 10385320
We have identified a heptapeptide with high affinity to rheumatoid arthritis-associated class II major histocompatibility (MHC) molecules. Using a model of its interaction with the class II binding site, a...
4.
Siklodi B, VOGT A, Kropshofer H, Falcioni F, Molina M, Bolin D, et al.
Hum Immunol
. 1998 Aug;
59(8):463-71.
PMID: 9712349
The effect of peptide length on the stability of peptide-HLR-DR1 (DR1) complexes was analyzed using two peptide series of increasing length, each containing a 7mer core with five DR1-binding anchors,...
5.
Vidovic D, Toral J, Bolin D, Ito K, Nagy Z
Scand J Immunol
. 1998 Mar;
47(3):191-4.
PMID: 9519855
Splenic cells from transgenic mice, in which a single peptide is complexed to all major histocompatibility complex (MHC) class II molecules, are found to be incapable of triggering primary allogeneic...
6.
Xia M, Sreedharan S, Bolin D, Gaufo G, Goetzl E
J Pharmacol Exp Ther
. 1997 May;
281(2):629-33.
PMID: 9152366
Ro 25-1392 [Ac-Glu8,OCH3-Tyr10,Lys12,Nle17,Ala19,A sp25,Leu26,-Lys27,28-vasoactive intestinal peptide(cyclo 21-25)] is a cyclic peptide analog of vasoactive intestinal peptide (VIP) that potently exerts cellular effects typical of VIP. The selectivity of Ro 25-1392...
7.
Ito K, Bian H, Molina M, Han J, Magram J, Saar E, et al.
J Exp Med
. 1996 Jun;
183(6):2635-44.
PMID: 8676084
To investigate the development of HLA-DR-associated autoimmune diseases, we generated transgenic (Tg) mice with HLA-DRA-IE alpha and HLA-DRB1*0401-IE beta chimeric genes. The transgene-encoded proteins consisted of antigen-binding domains from HLA-DRA...
8.
Bolin D, Cottrell J, Garippa R, Rinaldi N, Senda R, SIMKO B, et al.
Drug Des Discov
. 1996 Apr;
13(3-4):107-14.
PMID: 8874048
A series of i-->i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biological activity. In...
9.
Vidovic D, Falcioni F, Siklodi B, Belunis C, Bolin D, Ito K, et al.
Eur J Immunol
. 1995 Dec;
25(12):3349-55.
PMID: 8566022
Certain HLA class II-specific monoclonal antibodies (mAb) cause up to 90% decrease in the cell surface expression of class II molecules. This down-regulation is isotype-specific, i.e. DR-specific mAb do not...
10.
Bolin D, Cottrell J, Garippa R, Michalewsky J, Rinaldi N, SIMKO B, et al.
Int J Pept Protein Res
. 1995 Sep;
46(3-4):279-89.
PMID: 8537181
From previous work, the primary functional groups, i.e. side chains, of the vasoactive intestinal peptide which are responsible for interaction with the VIP receptor have been identified. One of these...